The aging populations in Poland, Germany and Switzerland are significantly driving the Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) markets. In Poland, the demographic shift is resulting in a higher prevalence of chronic illnesses such as diabetes, cardiovascular diseases, and cancer, which often require long-term nutritional support. Elderly patients frequently struggle with nutrient intake due to swallowing difficulties and gastrointestinal disorders, increasing the demand for HEN and HPN. These therapies provide continuous, personalized care at home, enhancing quality of life and reducing hospital readmissions.
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/poland-germany-and-switzerland-home-parenteral-nutrition-and-home-enteral-nutrition-market
Data Bridge Market Research analyzes that the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) Market is expected to reach USD 615.21 million by 2031 from USD 458.50 million in 2023, growing at a CAGR of 4.1% in the forecast period of 2024 to 2031.
Key Findings of the Study
Rising Prevalence of Chronic Diseases
The rising prevalence of chronic diseases such as cancer, gastrointestinal disorders, and metabolic diseases has significant implications for the Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) markets in Poland, Germany and Switzerland. These chronic conditions often lead to difficulties in nutrient intake and absorption, making long-term nutritional support essential for managing symptoms and improving patient outcomes. HPN and HEN therapies play a crucial role in addressing these challenges by providing tailored nutrition solutions that meet the specific needs of patients with chronic illnesses.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product & Services (Product and Services), Care Type (Pre-Operative Care and Post-Operative Care), Patient Type (Neurology Problems, Cancer, Abnormal Bowel Function, Crohn's Disease, Gastroparesis, and Others), Distribution Channel (B2B Channel and B2C Channel)
|
|
Countries Covered
|
Poland, Germany, and Switzerland
|
|
Market Players Covered
|
Fresenius SE & Co. KGaA (Germany), Nestlé (Switzerland), Abbott (U.S.), B. Braun SE (Germany), Baxter (U.S.), CSL (Australia) Nutricia (Netherland), and Pfizer Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) market is segmented into four notable segments which are based on product & services, care type, patient type, and distribution channel.
- Based on product & services, the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) market is segmented into product and services
In 2024, the product segment is expected to dominate the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) Market
In 2024, the product segment is expected to dominate the market with a market share of 71.67% in Poland, 71.79% in Germany, and 71.94% in Switzerland due to innovations in medical devices, nutrition formulations, and delivery systems enhancing efficacy, safety, and patient convenience.
- Based on care type, the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) market is segmented into pre-operative care and post-operative care
In 2024, the pre-operative segment is expected to dominate the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) Market
In 2024, the pre-operative segment is expected to dominate the market with a market share of 60.45% in Poland, 60.62% in Germany, and 60.84% in Switzerland due to the increasing recognition of nutritional optimization before surgeries to improve patient outcomes and recovery.
- Based on patient type, the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) market is segmented into neurology problems, cancer, abnormal bowel function, crohn's disease, gastroparesis, and others. In 2024, the neurology problems segment is expected to dominate the market with a market share of 28.20% in Poland, 28.50% in Germany, and 28.90% in Switzerland
- Based on distribution channel, the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) market is segmented into B2B channel and B2C channel. In 2024, the B2B channel segment is expected to dominate the market with a market share of 65.16% in Poland, 65.31% in Germany, and 65.50% in Switzerland
Major Players
Data Bridge Market Research recognizes the following companies as the major market players in the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) market are Fresenius SE & Co. KGaA (Germany), Nestlé (Switzerland), Abbott (U.S.), B. Braun SE (Germany), Baxter (U.S.).
Market Developments
- In February 2024, Fresenius Kabi advanced its collaboration with the European Society for Intensive Care Medicine (ESICM) to enhance research and medical training in intensive care, underpinning educational initiatives and professional development. This strategic partnership strengthened Fresenius Kabi's position in clinical nutrition by fostering innovation and expertise, ultimately driving better patient outcomes and reinforcing the company's leadership in the healthcare sector
- In April 2023, Fresenius Medical Care received the CIO 100 Award for its innovative tool predicting intradialytic hypotension in hemodialysis patients. This success underscored Fresenius Kabi's commitment to technological advancements, enhancing their clinical nutrition solutions by integrating predictive analytics to improve patient outcomes
- In March 2022, Fresenius Kabi acquired a majority stake in mAbxience and purchased Ivenix to drive strategic growth in Biopharmaceuticals and MedTech. This strengthened Fresenius Kabi's Clinical Nutrition division by enhancing its product offerings and expanding its technological capabilities, ultimately improving patient care and market reach
- In October 2023, Nestlé announced a collaboration with Amwell to enhance patient outcomes through digital nutrition solutions. Their first initiative, the Advanced Surgical Nutrition Automated Care Program, combined Amwell’s virtual technology with Nestlé’s Impact ADVANCED RECOVERY drink to support surgical recovery. This collaboration benefited Nestlé by strengthening its position in the Home Enteral Nutrition (HEN) market, showcasing their commitment to integrating nutrition and technology to improve clinical outcomes
- In February 2022, Nestlé supported Feeding Tube Awareness Week from February 7th to 11th, 2022, to highlight the benefits of feeding tubes as life-saving interventions. The company shared information about their medical nutrition products, including nutritional supplements, tube feeds, and food thickeners. This initiative raised awareness about tube feeding and the importance of medical nutrition, benefiting Nestlé Health Science by showcasing their expertise and commitment to improving patient care. Through this effort, they strengthened their relationship with healthcare professionals and the public
- In June 2024, Abbott announced FDA clearance for two new over-the-counter CGM systems, Lingo and Libre Rio, based on their FreeStyle Libre technology. Lingo is designed for consumers aiming to improve health and wellness, while Libre Rio is for adults with Type 2 diabetes who manage their condition through lifestyle changes
- In March 2024, Abbott, Real Madrid, and the Real Madrid Foundation have extended their partnership through the 2026-27 season, focusing on health and nutrition for children globally. This extension will enhance Abbott's role in providing nutrition education and malnutrition screening at Real Madrid Foundation Social Sports Schools, strengthening its commitment to global health and reinforcing its brand reputation
- In January 2024, Abbott, a global leader in science-based nutrition, stated today the launch of its new PROTALITY™ brand. The high-protein nutrition shake is the first product in this line to support the growing number of adults interested in following weight loss while maintaining muscle mass and good nutrition
- In May 2023, Abbott unveiled new programs in its ongoing effort to enhance diversity in clinical trials and healthcare for underrepresented groups. These additions to the Diversity in Clinical Trials initiative expand on partnerships, scholarships, and efforts to include diverse participants in Abbott's clinical trials. This initiative will not only improve healthcare outcomes for underrepresented populations but also enhance the company's understanding of how its products perform across diverse patient groups, ultimately leading to more inclusive and effective healthcare solutions
- In June 2022, Easterseals has received a USD750,000 grant from the Abbott Fund to launch the Project on Education and Community Health Equity. This three-year pilot initiative, running through 2025, targets systemic barriers to education and healthcare in underinvested communities. This project not only demonstrates Abbott's commitment to improving health and education access but also aligns with their corporate social responsibility goals, fostering goodwill and positive brand perception
- In January 2023, Nutricia introduces Fortimel PlantBased Energy, its pioneering plant-based medical nutrition drink aimed at addressing the nutritional needs of individuals following vegan, vegetarian, or flexitarian diets, as well as those with cow’s milk protein allergy. Developed to support patients at risk of malnutrition due to illness, this ready-to-drink supplement offers a complete nutritional profile, featuring high-quality plant proteins derived from pea and soy sources. Available in Mango & Passion Fruit and Mocha (Coffee & Chocolate) flavours, the product has been clinically proven to enhance protein and energy intake while demonstrating high patient adherence over a 4-week study period. Nutricia, leveraging Danone’s expertise in plant nutrition, launches Fortimel PlantBased Energy initially in several European countries, with plans for wider distribution throughout 2023. This innovation underscores Nutria’s commitment to providing tailored nutritional solutions aligned with diverse dietary preferences and medical needs
For more detailed information about the Poland, Germany and Switzerland Home Parenteral Nutrition (HPN) and Home Enteral Nutrition (HEN) market report, click here – https://www.databridgemarketresearch.com/de/reports/poland-germany-and-switzerland-home-parenteral-nutrition-and-home-enteral-nutrition-market
